Therapy for lower-risk MDS.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Lower-risk myelodysplastic syndromes (MDS) are defined by specific clinical and molecular criteria, including low blast counts and favorable karyotypes.
• The Revised International Prognostic Scoring System (R-IPSS) score of ≤3.5 categorizes patients into lower-risk MDS.
• Understanding mutational profiles aids in predicting the clinical behavior of lower-risk MDS.

Observation:

• Supportive care remains central to managing lower-risk MDS.
• Erythropoiesis-stimulating agents, lenalidomide, and luspatercept are effective for anemia in transfusion-dependent patients.
• Thrombopoietin receptor agonists are options for isolated thrombocytopenia, and hypomethylating agents or anti-thymocyte globulin for pancytopenia or severe symptoms.

Findings:

• Current treatments for lower-risk MDS primarily address symptomatic cytopenias, particularly anemia and thrombocytopenia.
• While these therapies can provide long-term benefits, progression to higher-risk MDS is a common outcome.
• Emerging targeted therapies show promise for specific molecular subsets, but approved mutation-directed treatments are not yet available.

Implications:

• Optimized supportive care and emerging targeted therapies can improve outcomes for lower-risk MDS patients.
• Longitudinal monitoring of mutational profiles is essential for guiding treatment and predicting disease progression.
• Further research into mutation-directed therapies is needed to address unmet needs in MDS treatment.